We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

CytRx Corp (CYTR) USD0.001

Sell:$0.60 Buy:$0.60 Change: $0.0001 (0.02%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.0001 (0.02%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
Change: $0.0001 (0.02%)
Market closed |  Prices as at close on 26 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology and rare diseases. The Company is focused on the discovery, research and clinical development of anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The Company's Linker Activated Drug Release (LADR) technology platform is a discovery engine to create a pipeline of anti-cancer molecules that avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. Its product candidate, Aldoxorubicin is a rationally engineered cytotoxic which delivers anti-cancer agent, doxorubicin, into the tumor is in late-stage clinical trials. Its other product candidate, Arimoclomol is also in clinical trials for Niemann Pick disease Type C (NPC) and Gaucher disease through Orphazyme A/S.

Contact details

11726 San Vicente Blvd Ste 650
United States
+1 (310) 8265648

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$23.27 million
Shares in issue:
38.78 million
Off Exchange
United States
US dollar

Key personnel

  • Steven Kriegsman
    Chairman of the Board, Chief Executive Officer
  • John Caloz
    Chief Financial Officer, Chief Accounting Officer, IR Contact Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.